Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To clarify: I mentioned two years as the historical review period, not two years of continuous monitoring starting from the initiation of an audit.
One of the most challenging elements of a two year audit for a manufacturer is the inventory roll back. Every purchase of each and every component/material has to be accounted for along with what it was used to build and who it was sold to. The date and price must be matched up to align with the physical inventory count that the auditors performed on a specific date within the two year period. Once competed, it is essentially there is a broad selection of elements that is picked by the auditors for review and confirmation as a nearly final step of the overall process.
Unfortunately, controlling shareholders have far more control that people realize. Most pink sheet managers use their powers & abilities for personal gain while punishing shareholders, it is not hard to do.
Yes, good point. This could've been another effective bargaining chip against the OMID-held GDVM shares.
GDVM has a large majority stockholder who is also the managing director or an affiliate. In that position, with OMID as the other significant shareholder and only holding 525M common shares (roughly 12% of the OS), the managing director had the ability and the motive to threaten to RS (and ultimately dilute OMID's stake).
This would have been difficult to counter due to the fact that the shares OMID held were only recently discovered as certificates from around 2011 without any transaction history or deal tied to them. As such, the shares were restricted from sale as part of the public float - leaving OMID with limited option to monetize them. When they received an (potentially threatening) offer, it may have been the best option.
If you ask me, it makes no sense for a shell to be trading at the market cap that GDVM is at but apparently the draw of a speculative gamble (more like a game of musical chairs) has apparently been enough to drive it for now.
Executive common shares dropped by 164M which was the overwhelming majority of total insider-held common shares.
The executives had about 7 or 8 million common shares at that time and the total common held by Adam and Kevin has not increased, ever.
I want a similar buy.
OMID
with prejudice
When a court dismisses an action, they can either do so “with prejudice” or “without prejudice.” Dismissal with prejudice means that the plaintiff cannot refile the same claim again in that court.
The reason that dismissal with prejudice prevents subsequent refiling is because this type of dismissal is considered an “adjudication on the merits.” An adjudication on the merits means that the court has made a determination on the legal and factual issues of the claim. Once a plaintiff’s claim is adjudicated on the merits, they cannot bring the same claim again. The source of this rule lies in the doctrine of res judicata.
Yes it is still certainly a priority.
I hate to delay and miss the original target.. so many trash companies fruitlessly dangle the uplist carrot for years.. but that's what happened as we were supposed to be nearing the finish line in Q2. The accountant's assistant became the only contact that could finally be reached.
Without asking for our money back - we were simply inquiring about our audit status - she immediately refunded the past several months of payments.
I would say that we are in better hands now with our new accountant than we were before but it was not the desired outcome at the time.
I spent a lot of time reading filings years ago.. of course I still do if I am going to trade, especially for OTC.
One of the first things I always do when initiating DD is check for any kind of financing for convertible notes, recent placement pricing, toxic debts, and other things that may just be an immediate signal to flee.
Reading it all is no doubt a good practice and even better if you need practice to understand it!
Subsequent events is a good one to swiftly check on the ones you're familiar with.
Enjoy the weekend guys.
Likely someone who either has no clue what they are doing or badly needs cash.
Insiders can only sell up to 1% of total OS per quarter.. and this is actually a rolling total per 90-day time period. It would be less than 1M shares per executive/insider with the current OS.
OMID
It must be 100 shares at minimum to change ticker price at this price level.
Hopefully a video interview will be posted soon.
OMID
Congrats.. good riddance to the 1M share panic-seller.
Makes little sense as anything but a stop hunt by the MMs, perhaps screwing a long who made a mistake.
Nice find Rip, that was more informative than expected.
AVOP was quite the pump job at the time ey?
I liked all the pies in the skies and then one little part that said something along the lines of "although the revenue is currently negligible, if they do $30M in revenue this year, it may amount to as much as $3M in operating profits"
Lol. Thanks for the sage wisdom "Goldman".
Nice read on this, Bubae, always appreciate a well-informed post.
There have been many of those on this board lately.
It is nice to see many familiar faces here from back in the day, I hope you all have been well.
OMID means hope.
I've personally been very comfortable with ALEAF with respect to the possibility of dilution or financing of any kind. They clearly have a ton of cash and were moving into some very nice price points and subsequent margins which is clearly leading to profitable operations at my last review not too long ago.
Another interesting development was that they had approved an RS but dropped that as they had promising developments and clearly expected the stock to recover itself.
I've been quite patient with loading but I'm certainly looking forward to an update and snapshot the company come March 18. I consider this one of the most promising players in the industry ad they have clearly gone for quality (low operating and production costs) over quantity (less initial emphasis on capacity which most others prioritized at any cost and cannot profitably utilize).
OMID
This stock trades like a tumbleweed.
It is so light and thin that it tumbles in either direction at the mere potential of a buy/sell.
It's going to get air on the good ER IMO.
OMID
Can't wait for ER and especially the section: "Subsequent Events"
Just added 30K at .54
GLTA
OMID
Just slapped high .53s to .5427 for 20K
Current chart is oversold - below bottom bollinger at .54 - and the ER is upcoming. I suspect it will begin the next push and potentially running in anticipation of a great ER shortly.
GLTA
OMID
I've been running a CBD business for past 4 years so trust me, I'm well aware of is potential for growth and human/animal benefits.
Glty bro.
Omid
Seems like things are progressing as expected here.
Good luck all.
OMID
Chart is notably oversold here and appears to be bottoming per RSI and slow stochastics.
Approaching break-even on the relatively small number of warrants below $1 which are priced at .5 and .55 per unit. With that said: this weakness is starting to appear truly irrational and overdone; I'm nearly out of explanations for it other than MMs or similar entities loading for a run.. we obviously wouldn't expect any sort of pending or inevitable financing activities to be an incentive to push it lower considering their significant cash position.
With respect to cash: we can expect it to be larger than last reported due to reported profitability and a deposit refund from the recently-terminated Aphria supply agreement.
OMID
I was not aware of that but I often find that it helps to think what a MM would do.
This information certainly provides a good insight into the sector weakness lately, as MMs would crush the stocks to load up if they intend to run them leading up to and after news.
Honestly, I was expecting the whole sector to continue to fade, especially through tax loss selling... bottoming in December and beginning and new bullish sector outlook near the end of 2019 and into the start of 2020.
As for ALEAF: we may see a bit of action before EOY. The confidence of management to cancel their approved R/S ("share consolidation") was a welcome, quite rare surprise... especially since it is currently trading below a dollar.
OMID
Good observation - seemed worth 1 of your 2 posts per year since 2008 :-p
I grabbed an initial position of 10K shares at .61x
We're about a month from the 10-Q showing profitability, hopefully it's not a one-off and is easily considered repeatable.
We should be getting some more good news about the other facility and confirmation on the harvest. Either way, it is oversold and only ~700K warrants can be exercised at 0.50-0.55 where the others are considerably higher. So I don't see much rationale for this downward pressure.
OMID
Bailing on that supply agreement eliminates a huge liability (a 2 year commitment of roughly $100M). It really gives some insight into the maturity of the company. I wonder how much of the $22M+ deposit (as of June 30, 2018) will return to the company.
OMID
https://backend.otcmarkets.com/otcapi/company/financial-report/227607/content
Agreed, I found it odd that the article didn't give a whole lot - perhaps zero - indication of the massive growth footprint increases that have recently been approved or are soon to be approved by health Canada. The author certainly made that a mainstay of the first stock mentioned. Presumably spicing up the article with international import export and not repeat same things.
OMID
Is most of the volume going through dark pools or something?
I'm not seeing anywhere near the 6.5M volume going through on L2 or time&sales here..
OMID
Really would like to know why this keeps spiking on high volume.
Are the alleged buyers locking up the float before BO or are the note holders pushing it to convert and short against their conversions at .1385?
My understanding - which is a bit dated now - is that the conversions were nearly finished from the Series B Preferred shares.
Edit: it briefly slipped my mind that there was the 25:1 RS. So those convert at $3.4625 assuming no recent adjustments.
OMID
Just came across this stock while researching CTST - a chart which I found to be interesting upon first glance this morning.
I am quite impressed with the recent announcements and growth of ALEAF in the past 6 months and even more surprised to see that the share price is as low as it is - lower since the rumors of taking over CTST.
This seems likes a solid long term growth investment - now I am mainly trying to decide if I want to continue to hold my CTST (purchased today at $1.95 per share) and pray for the acquisition by ALEAF valued at $4 per CTST share or directly purchase stock in ALEAF.
As far as risk:reward analysis goes: buy and hold of ALEAF seems to be a great option.
OMID
The released particles are essentially passivized by the body's immune system. This leads to other complications - inflammation and stress on the body.
CoCr and Ti are selected due to this not being as large of an issue but still more than ceramic.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793669/
Forgive the delay, boston.
Been very busy lately and just hibernating with my AMDA stashed away.
The electrical charge is extremely localized to the implants - quite insignificant the the body; however, to the implant it means pitting corrosion is possible and likely. The overall consequence and evidence of the corrosion is reduced due to wear on the articulating joint surfaces that are prone to wear.
OMID
The fact that the material is charged means that it would be susceptible to pitting corrosion when suspended in any medium with electrolytes, including blood.
OMID
Daily chart looks great for a pop over the next 5 days or so.
I'm in at .81
OMID
I confirmed this with an institution.
There must have been some covenant in the warrants that allow them to be repriced in the event that some other asset liability is converted at a price lower than $1.6 - so conversions of Series B at $0.48/share re-priced warrants.
Either way, the details of how are not important to me.
OMID
The warrants were re-priced to 0.48/share
The Series B remain at 0.48/share floor.
OMID
RE: Series B Preferred Floor Conversion Price
From SEC 2Q 10-Q Filing:
http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=12918746-890-124317&type=sect&TabIndex=2&companyid=603456&ppu=%252fdefault.aspx%253fsym%253dAMDA
I am not on board with this explanation of dividends priced below 0.48
In fact, to play devil's advocate with your theory: the company initially issued Units which were thereafter automatically converted into the warrants and the series b.
Omid
I am not aware of a way for series b to profit below .436 (0.48-9.17%)
I will verify this on Monday.